KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)

Vir Biotechnology's Change in Receivables history spans 4 years, with the latest figure at $8.7 million for Q4 2024.

  • For Q4 2024, Change in Receivables rose 142.57% year-over-year to $8.7 million; the TTM value through Dec 2024 reached $6.5 million, up 1052.74%, while the annual FY2024 figure was $6.5 million, 1052.74% up from the prior year.
  • Change in Receivables for Q4 2024 was $8.7 million at Vir Biotechnology, up from $54000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $680.1 million in Q4 2021 and bottomed at -$883.8 million in Q2 2022.
  • The 4-year median for Change in Receivables is $54000.0 (2024), against an average of $778384.6.
  • The largest YoY upside for Change in Receivables was 142.57% in 2024 against a maximum downside of 183.65% in 2024.
  • A 4-year view of Change in Receivables shows it stood at $680.1 million in 2021, then tumbled by 140.9% to -$278.2 million in 2022, then soared by 101.3% to $3.6 million in 2023, then skyrocketed by 142.57% to $8.7 million in 2024.
  • Per Business Quant, the three most recent readings for VIR's Change in Receivables are $8.7 million (Q4 2024), $54000.0 (Q3 2024), and -$2.7 million (Q2 2024).